Logically, any treatment that could decrease PSA levels in prostate cancer cells, or antagonize specific androgen hormone action, would have great potential in addressing prostate disorders, such as benign prostatic hyperplasia (BPH) or prostate cancer. This evidence concerns the gene KLK3 and prostate disorder.